The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis

Buysse, 2013, Insomnia, Jama, 309, 706, 10.1001/jama.2013.193 Walsh, 2011, Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS), Sleep, 34, 997, 10.5665/SLEEP.1150 Roth, 2011, Biol Psychiatr, 69, 592, 10.1016/j.biopsych.2010.10.023 Morin, 2009, The natural history of insomnia: a population-based 3-year longitudinal study, Arch Intern Med, 169, 447, 10.1001/archinternmed.2008.610 Kessler, 2011, Insomnia and the performance of US workers: results from the America insomnia survey, Sleep, 34, 1161, 10.5665/SLEEP.1230 Laugsand, 2011, Insomnia and the risk of acute myocardial infarction: a population study, Circulation, 124, 2073, 10.1161/CIRCULATIONAHA.111.025858 Abad, 2018, Insomnia in elderly patients: recommendations for pharmacological management, Drugs Aging, 35, 791, 10.1007/s40266-018-0569-8 de Lecea, 2014, Hypocretin (orexin) regulation of sleep-to-wake transitions, Front Pharmacol, 5, 16, 10.3389/fphar.2014.00016 Kukkonen, 2017, Orexin/hypocretin signaling, Curr Topic Behav Neurosci, 33, 17, 10.1007/7854_2016_49 Herring, 2012, Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant, Neurology, 79, 2265, 10.1212/WNL.0b013e31827688ee Michelson, 2014, Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial, Lancet Neurol, 13, 461, 10.1016/S1474-4422(14)70053-5 Herring, 2016, Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials, Biol Psychiatr, 79, 136, 10.1016/j.biopsych.2014.10.003 Herring, 2020, Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial, Alzheimers Dement, 16, 541, 10.1002/alz.12035 Hoever, 2012, Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial, Clin Pharmacol Ther, 91, 975, 10.1038/clpt.2011.370 Roth, 2017, Dual orexin receptor antagonist, almorexant, in elderly patients with primary insomnia: a randomized, controlled study, Sleep, 40, 10.1093/sleep/zsw034 Black, 2017, Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference, Sleep Med, 36, 86, 10.1016/j.sleep.2017.05.009 Connor, 2016, A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia, Int J Neuropsychopharmacol, 19, 10.1093/ijnp/pyw022 Murphy, 2017, Lemborexant, A dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study, J Clin Sleep Med : JCSM : Off Pub Am Acad Sleep Med, 13, 1289 Rosenberg, 2019, Comparison of lemborexant with placebo and Zolpidem Tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial, JAMA Network Open, 2, 10.1001/jamanetworkopen.2019.18254 Kärppä, 2020, Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2, Sleep, 43, 10.1093/sleep/zsaa123 Zammit, 2020, Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder, Neurology, 94, e2222, 10.1212/WNL.0000000000009475 Dauvilliers, 2020, Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder, Ann Neurol, 87, 347, 10.1002/ana.25680 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700 Kario, 2019, Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: the SUPER-1 study, J Clin Hypertens (Greenwich), 21, 896, 10.1111/jch.13505 Roehrs, 2020, Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo, J Clin Sleep Med, 16, 415, 10.5664/jcsm.8220 De Boer, 2018, A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity, J Psychopharmacol, 32, 668, 10.1177/0269881118773745 Brooks, 2019, The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia, J Psychopharmacol, 33, 202, 10.1177/0269881118822258 Recourt, 2019, The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder, Transl Psychiatr, 9, 216, 10.1038/s41398-019-0553-z Wilt, 2016, Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American college of physicians, Ann Intern Med, 165, 103, 10.7326/M15-1781 Buscemi, 2007, The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs, J Gen Intern Med, 22, 1335, 10.1007/s11606-007-0251-z Everitt, 2018, Antidepressants for insomnia in adults, Cochrane Database Syst Rev, 5, CD010753 Auld, 2017, Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders, Sleep Med Rev, 34, 10, 10.1016/j.smrv.2016.06.005 Kuriyama, 2017, Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis, Sleep Med Rev, 35, 1, 10.1016/j.smrv.2016.09.004 Yoshida, 2014, Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists, Bioorg Med Chem, 22, 6071, 10.1016/j.bmc.2014.08.034 Scott, 2020, Lemborexant: first approval, Drugs, 80, 425, 10.1007/s40265-020-01276-1 Kishi, 2020, Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis, J Psychiatr Res, 128, 68, 10.1016/j.jpsychires.2020.05.025 Brisbare-Roch, 2007, Promotion of sleep by targeting the orexin system in rats, dogs and humans, Nat Med, 13, 150, 10.1038/nm1544 Chabi, 2015, Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis, Cephalalgia, 35, 379, 10.1177/0333102414544979 Joseph Herring, 2018, Orexin receptor antagonism in painful diabetic neuropathy: a phase 2 trial with filorexant, Clin J Pain, 34, 37, 10.1097/AJP.0000000000000503 Connor, 2017, Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder, Int J Neuropsychopharmacol, 20, 613, 10.1093/ijnp/pyx033